10x Genomics (TXG) executive compensation, 2026 proxy

Serge Saxonov, Chief Executive Officer, was paid $6.3M in 2025, down 20% from $7.9M the year before. The CEO-to-median-employee pay ratio was 32:1, on median employee pay of $196,532.

Filed
April 24, 2026
Annual meeting
June 4, 2026
Pay year
2025
Named executives
4
CEO total pay
$6.3M-20% vs prior year
CEO to median employee
32:1median $196,532
CEO pay in equity
79%$5M in awards
Prior say-on-pay support
84%of votes cast
Revenue Growth
5%Year-over-year increase
Cash Balance Increase
$130MYear-over-year increase
Gross Margin
69%Fiscal year 2025
Corporate Goal Achievement
93%For Annual Incentive Plan

How Saxonov was paid

$6.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary11%Stock awards79%Non-equity incentive10%

Named executive officers

ExecutiveTotal
Serge SaxonovChief Executive Officer$6,329,244
Adam S. TaichChief Financial Officer$2,233,107
Benjamin J. HindsonPresident and Chief Scientific Officer$2,604,759
Eric S. WhitakerFormer Chief Legal Officer$3,441,571

What changed and why

  • $1.6MChief Executive Officer total compensation decreased by $1.6M in 2025 due primarily to smaller annual equity awards.
  • $643MRevenue increased 5% year-over-year to $643 million, which included $44 million of non-recurring patent litigation settlements.
  • 93%Annual Incentive Plan bonuses were paid based on 93% corporate goal achievement.
  • $130MCash and cash equivalents and marketable securities increased by $130 million year-over-year to $523 million.
  • 90%More than 90% of the Chief Executive Officer's target total compensation was at-risk.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.